Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 6/20 | 0.67 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.67 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.67 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.65 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.64 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.62 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.60 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.60 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.60 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.60 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19536257 | 1.00 | P2RX3 (0.67) | P2RX3P2RX4P2RX1P2RX2ADORA2A | |
| SCHEMBL21008117 | 1.00 | P2RX3 (0.67) | P2RX3P2RX4P2RX1P2RX2ADORA2A | |
| SCHEMBL30597830 | 1.00 | P2RX3 (0.67) | P2RX3P2RX4P2RX1P2RX2ADORA2A | |
| SCHEMBL14929329 | 1.00 | P2RX3 (0.67) | P2RX3P2RX4P2RX1P2RX2ADORA2A | |
| SCHEMBL14853798 | 1.00 | P2RX3 (0.67) | P2RX3P2RX4P2RX1P2RX2ADORA2A | |
| SCHEMBL18561528 | 1.00 | P2RX3 (0.67) | P2RX3P2RX4P2RX1P2RX2ADORA2A | |
| SCHEMBL19535617 | 1.00 | P2RX3 (0.67) | P2RX3P2RX4P2RX1P2RX2ADORA2A | |
| SCHEMBL21007872 | 1.00 | P2RX3 (0.67) | P2RX3P2RX4P2RX1P2RX2ADORA2A | |
| SCHEMBL16199307 | 0.92 | ADORA2A (0.62) | P2RX3P2RX4P2RX1P2RX2ADORA2A | |
| SCHEMBL16572758 | 0.92 | ADORA2A (0.62) | P2RX3P2RX4P2RX1P2RX2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013340-B9 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3013340-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210106604-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2021-04-15 | — | — | US | disclosed |
| EP-3797782-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | Janssen BioPharma, Inc. (US) | 2021-03-31 | — | — | EP | disclosed |
| US-10780105-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190307783-A1 | USE OF ANTIVIRALS TO INHIBIT PROTOZOAN VIRUSES | WASHINGTON UNIVERSITY | 2019-10-10 | — | — | US | disclosed |
| US-10370401-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
| US-10307439-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190054108-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2019-02-21 | — | — | US | disclosed |
| WO-2015054465-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-04-16 | — | — | US | disclosed |
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-04-16 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
| WO-2014209979-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| US-20130064794-A1 | Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20120039845-A1 | NUCLEOSIDE PRODRUGS AND USES THEREOF | METABASIS THERAPEUTICS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8063025-B2 | Nucleoside prodrugs and uses thereof | METABASIS THERAPEUTICS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090209481-A1 | Nucleoside prodrugs and uses thereof | ROCHE PALO ALTO LLC | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10307439-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, TYMP | P2RX3 240/4885P2RX4 179/4885P2RX1 196/4885 |
| US-20190054108-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | P2RX3 166/4885P2RX4 154/4885P2RX1 140/4885 |
| US-20120039845-A1 | NUCLEOSIDE PRODRUGS AND USES THEREOF | PNP, RNGTT, NSUN2 | P2RX3 986/4885P2RX4 721/4885P2RX1 597/4885 |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | P2RX3 140/4885P2RX4 139/4885P2RX1 119/4885 |
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | P2RX3 100/4885P2RX4 99/4885P2RX1 83/4885 |
| US-10370401-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, NUDT1 | P2RX3 100/4885P2RX4 99/4885P2RX1 83/4885 |
| US-20090209481-A1 | Nucleoside prodrugs and uses thereof | PNP, RNGTT, NSUN2 | P2RX3 960/4885P2RX4 746/4885P2RX1 571/4885 |
| US-10780105-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C3B | P2RX3 166/4885P2RX4 154/4885P2RX1 140/4885 |
| US-20130064794-A1 | Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | PYGL, HAVCR2, PNP | P2RX3 649/4885P2RX4 713/4885P2RX1 1081/4885 |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | P2RX3 90/4885P2RX4 75/4885P2RX1 79/4885 |
| US-20210106604-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | P2RX3 166/4885P2RX4 154/4885P2RX1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.